The Senate health committee is soliciting feedback from key stakeholders on how to modernize the Clinical Laboratory Improvement Amendments (CLIA) as a solution for government oversight of laboratory-developed tests, while House Energy & Commerce lawmakers simultaneously reach out to stakeholders on an alternative legislative proposal that would set up a new FDA center responsible for in vitro tests. Industry groups remain split on how to tackle the issue, with the American Clinical Laboratory Association (ACLA) continuing to favor a CMS-led...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.